BioSpace News Archive

Juvenescence, a life sciences company targeting the intrinsic mechanisms of aging, announces that Colin Watts has joined its Management Team as CEO of Juvenescence Life.

Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases, today announced that it has entered into a collaboration agreement with Paragon Gene Therapy, a unit of Catalent Biologics, for the development of a dedicated manufacturing suite at their facility near Baltimore, Maryland.

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it is hosting a webinar that will present the latest in vitro research methods and International Transporter Consortium (ITC) guidance for assessing bile salt export pump (BSEP) inhibition to reduce and manage the risk of drug-induced liver injury (DILI) during drug development.

ObjectiveGI is delivering provider partners and their patients participating in research a new, all-inclusive platform of clinical research data management.

On July 10th, Chengdu Hi-tech Zone and Gilead Sciences inked a strategic cooperation agreement on the Gilead Sciences Western China Operation Center project, which marked the official registration of its western China operation center in Chengdu Hi-tech Zone.

Greene Tweed, a leading global manufacturer of high-performance seals, thermoplastics, composites, and engineered components, highlights its sealing solutions for pharmaceutical processing.

The Centers for Disease Control and Prevention (CDC) estimates that approximately 300,000 people will be infected with Lyme disease each year in the United States.

Gilead will provide funding to Renown IHI to sequence and analyze the DNA of 15,000 individuals living with NASH or nonalcoholic fatty liver disease (NAFLD) as well as a control cohort of 40,000 individuals in Nevada.

Nordic Nanovector ASA (OSE: NANO) announces that the final patient has been enrolled in the LYMRIT 37-05 clinical trial of Betalutin® (177Lu-satetraxetan-lilotomab) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not eligible for stem cell transplantation.

Alinity™ s System will screen the U.S. blood and plasma supply faster and more efficiently while maintaining highest levels of accuracy